Stomach Cancer

Stomach Cancer: treatments, trials & survival

Stomach (gastric) cancer treatment includes surgery, chemotherapy, and emerging immunotherapy options. Find clinical trials and treatment resources.

New Cases (2024)
26,890
5-Yr Survival
36.3%
Annual Deaths
10,880
Trend
Decreasing
See active trials

About Stomach Cancer

Stomach (gastric) cancer treatment includes surgery, chemotherapy, and emerging immunotherapy options. Find clinical trials and treatment resources.

According to the National Cancer Institute’s SEER database, an estimated 26,890 new cases of stomach cancer will be diagnosed in the United States in 2024, with approximately 10,880 deaths. The overall 5-year relative survival rate is 36.3%.

Source: NCI SEER Data: 1975–2022

Treatment options

Current treatment approaches for stomach cancer depend on the stage at diagnosis, tumor characteristics, and the patient’s overall health. The most common options include:

1
Surgery (Gastrectomy)
2
Chemotherapy
3
Radiation Therapy
4
Targeted Therapy (Trastuzumab for HER2+)
5
Immunotherapy (Nivolumab)
6
Perioperative Chemotherapy

Treatment recommendations should always be discussed with a qualified oncologist. The options listed above are based on current clinical guidelines and may vary case by case.

Stages

Staging describes the extent of cancer in the body and is crucial for planning the most appropriate treatment:

Stage I Stage II Stage III Stage IV

Known risk factors

Understanding risk factors can support prevention and early detection. Known risk factors for this cancer include:

H. pylori infection
Smoking
Diet high in smoked/pickled foods
Family history
Previous stomach surgery
Pernicious anemia

Not sure where to start?

A patient navigator familiar with stomach cancer can help you understand your options and connect you with top US hospitals. Free & confidential.

Active clinical trials

Clinical trials offer access to cutting-edge treatments not yet widely available. The trials below are sourced in real time from ClinicalTrials.gov:

Frequently asked questions

The 5-year relative survival rate for stomach cancer is 36.3%. Early detection improves outcomes significantly, with localized stomach cancer having a 75% survival rate.
Yes, nivolumab combined with chemotherapy is now a first-line treatment for advanced gastric cancer. Pembrolizumab is also approved for PD-L1-positive tumors.
H. pylori infection is the strongest known risk factor for stomach cancer. Treating the infection with antibiotics can reduce cancer risk, especially if treated early.
Perioperative chemotherapy is given both before (neoadjuvant) and after (adjuvant) surgery. The FLOT regimen is the current standard, improving survival compared to surgery alone.
You’re not alone

Looking for stomach cancer treatment options?

A patient navigator can help you explore treatment pathways, find clinical trials near you, and connect with specialists who see stomach cancer every day. Free, confidential consultation.

Send a message
Free callback

Talk to a navigator

Leave your details and we’ll call you at your preferred time.